论文部分内容阅读
报道5α-还原酶抑制剂(finasteride)治疗女性多毛症的随机对照单盲临床研究结果。试验组包括10例特发性多毛(19～26岁)及15例多囊卵巢综合征(PCOS)(20～30岁)患者,前组仅血清双氢睾酮(DHT)及其代谢产物3α,17β雄烷二醇葡萄糖醛酸盐(3α-diolG)浓度升高;后组测血清睾酮(T)、雄烯二酮(A)及去氢表雄酮硫酸盐(DHEAS)也升高。另收集特发性多毛及PCOS患者各7例(20～26岁)为对照组。试验组每日口服finasteride 5mg共6个月,对照组服安慰剂。服药前及服药3个月、6个月时行Ferriman-Gallway多毛评分并抽血测T、DHT、A、DHEAS及3α-diolG(RIA)。以T检验进行统计分析。
A single-blind randomized controlled clinical trial of 5α-reductase inhibitor (finasteride) in the treatment of female hirsutism was reported. The experimental group consisted of 10 patients with idiopathic hirsutism (19 ~ 26 years) and 15 patients with PCOS (20 ~ 30 years old) .Serum DHT and its metabolites 3α, 17β-androstanediol glucuronate (3α-diolG) was increased. Serum testosterone (T), androstenedione (DHEA) and DHEAS also increased in the latter group. Another collection of idiopathic hirsutism and PCOS patients in each of 7 cases (20 ~ 26 years old) as the control group. The experimental group daily oral finasteride 5mg for 6 months, the control group taking placebo. Before taking the drug and medication 3 months, 6 months, Ferriman-Gallway hairy score and blood tests T, DHT, A, DHEAS and 3α-diolG (RIA). T test for statistical analysis.